“THE Co-Occurrence of Jak2 Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated With Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated With Two Drug Association”. Mediterranean Journal of Hematology and Infectious Diseases 17, no. 1 (February 27, 2025): e2025023. Accessed April 17, 2026. https://www.mjhid.org/mjhid/article/view/5901.